Table 2.
Clinical Characteristics of Patients with Recurrence
| Patient | Sex | Age at diagnosis, yr |
EUS | ESD/ EMR |
Endoscopic size, mm | Pathologic size, mm | Grade (pathology) | Mitosis (/10HPF) | DOTA PET | Rectal MRI | Lesion of metastasis | Days of recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 54 | NA | EMR | 3 | Missing | Missing | Missing | NA | NA | Metachronous lesion | 454 |
| 2 | M | 33 | NA | ESD | 8 | 8 | 1 | <2 | NA | NA | Metachronous lesion | 400 |
| 3 | F | 57 | NA | EMR | 3 | 4 | Missing | <2 | NA | NA | Metachronous lesion | 1,269 |
| 4 | M | 39 | NA | EMR | 4 | 3.5 | Missing | <2 | NA | NA | Metachronous lesion | 401 |
| 5 | M | 61 | NA | ESD | 3 | 4 | Missing | <2 | NA | NA | Metachronous lesion | 2,279 |
| 6 | F | 50 | SM | ESD | 7.7 | 7 | 2 | 2-20 | NA | NA | Lymph node | 574 |
| 7 | M | 38 | NA | EMR | 3 | 6 | 1 | Missing | Done | Done | Metachronous lesion | 82 |
| 8 | M | 51 | NA | EMR | 3 | 2 | 1 | Missing | NA | NA | Metachronous lesion | 1,236 |
| 9 | M | 48 | NA | EMR | 3 | 3 | 1 | <2 | NA | NA | Metachronous lesion | 546 |
| 10 | M | 61 | SM | EMR | 6 | 4 | 1 | Missing | NA | NA | Focal | 314 |
| 11 | M | 50 | NA | EMR | 13 | 12 | 2 | >20 | NA | NA | Lymph node & liver metastasis |
1,656 |
| 12 | M | 67 | SM | ESD | 9 | 8 | 2 | >20 | NA | NA | Liver metastasis | 2,476 |
EUS, endoscopic ultrasonography; ESD, endoscopic submucosal dissection; EMR, endoscopic mucosal resection; HPF, high-power field; DOTA PET, 68Ga-labeled DOTA-peptide positron emission tomography; MRI, magnetic resonance imaging; NA, not available; SM, submucosa.